OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On March 2, 2020, Oxford Immunotec Global PLC (the “Company”) announced, via press release, its financial results for the quarter and full year ended December 31, 2019 (the “Press Release”). The Press Release is incorporated herein by reference solely for purposes of this Item 2.02 disclosure.
The Press Release is “furnished” as Exhibit 99.1 to this Current Report on Form 8-K to General Instruction B.2 of Form 8-K, and the information provided in this Item 2.02 of this report, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. The information provided in Item 2.02 of this report, including Exhibit 99.1 hereto, shall not be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
Oxford Immunotec Global PLC Exhibit
EX-99.1 2 ex_174732.htm EXHIBIT 99.1 ex_174732.htm Exhibit 99.1 Oxford Immunotec Reports Fourth Quarter and Full Year 2019 Financial Results ● Fourth quarter 2019 revenue of $18.1 million,…
To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
